Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innoviva (INVA) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Innoviva (INVA) over the last 17 years, with Q3 2025 value amounting to $476.5 million.

  • Innoviva's Cash & Equivalents rose 8283.12% to $476.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $476.5 million, marking a year-over-year increase of 8283.12%. This contributed to the annual value of $305.0 million for FY2024, which is 5759.35% up from last year.
  • Innoviva's Cash & Equivalents amounted to $476.5 million in Q3 2025, which was up 8283.12% from $397.5 million recorded in Q2 2025.
  • In the past 5 years, Innoviva's Cash & Equivalents ranged from a high of $476.5 million in Q3 2025 and a low of $43.3 million during Q2 2021
  • Its 5-year average for Cash & Equivalents is $242.1 million, with a median of $217.0 million in 2024.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 8952.79% in 2021, then skyrocketed by 55544.9% in 2022.
  • Innoviva's Cash & Equivalents (Quarter) stood at $201.5 million in 2021, then surged by 44.42% to $291.0 million in 2022, then crashed by 33.51% to $193.5 million in 2023, then skyrocketed by 57.59% to $305.0 million in 2024, then surged by 56.25% to $476.5 million in 2025.
  • Its Cash & Equivalents stands at $476.5 million for Q3 2025, versus $397.5 million for Q2 2025 and $319.1 million for Q1 2025.